Your patients' results depend on what happens in the 4-hour window after microneedling. CUVA R1 delivers GHK-Cu + PDRN at clinical concentration — sterile, single-dose, ready for the treatment room.
The 500 Dalton problem
The stratum corneum is an extraordinarily effective barrier. The 500 Dalton rule: molecules above 500 Da do not cross intact skin. Most cosmetic peptides sit on the surface and wash off — regardless of concentration.
Microneedling changes the equation. Aqueous microchannels 70–150µm wide form through the stratum corneum. Every peptide in the table becomes deliverable at concentrations approaching intradermal injection. Your patients are already creating this window. R1 uses it.
The biology does the work. Timing is everything.
See the R1 formula →| Peptide | MW (Da) | Intact skin |
|---|---|---|
| Argireline Acetyl Hexapeptide-8 |
888 | Negligible |
| Matrixyl Palmitoyl Tripeptide-1 |
~620 | Low to negligible |
| SYN-AKE Tripeptide-3 |
~696 | Negligible |
| GHK-Cu Copper Tripeptide-1 |
~341 | Low — at limit |
| PDRN Polydeoxyribonucleotide |
100k–250k | Zero passive |
GHK-Cu achieves 134 nmol/mg in skin tissue 9 hours post-microneedling — versus near-zero on untreated skin. Same peptide. Same concentration. The procedure is the delivery mechanism. CUVA R1 is formulated for that moment.
The clinical protocol
No new equipment. No new training. One additional step.
Perform your standard microneedling treatment. 300µm–1.5mm needle depth. R1 is compatible with dermarollers, dermapens, and RF microneedling devices.
Break the sterile glass ampoule immediately post-treatment. Apply to the treated area. No mixing, no preparation. Single-dose — one ampoule per patient per session.
R1 — Launching Q3 2026GHK-Cu activates collagen signalling and gene repair. PDRN engages the A2A receptor for anti-inflammatory and pro-synthesis response. Both delivered at concentrations that work.
Available for clinic supply
Recovery Ampoule · GHK-Cu + PDRN
GHK-Cu at clinical concentration. PDRN for the repair cascade. Multi-molecular-weight hyaluronic acid to open the microchannels and lock in the active layer.
The evidence is unambiguous. PDRN outperformed PRP in a direct RCT for wrinkle reduction. GHK-Cu modulates 4,000+ genes toward a younger fibroblast phenotype (Pickart & Margolina, IJMS 2018). No other post-microneedling product delivers both at these concentrations.
Sterile · Single-dose · 2 mL glass ampoule · No fragrance, acids, retinoids, or parabens
| Ingredient | Conc. | Role |
|---|---|---|
| GHK-Cu Copper Tripeptide-1 |
2–5% | Repair, collagen signalling, gene reset, antioxidant |
| PDRN Polydeoxyribonucleotide |
≥1% | Anti-inflammatory + pro-synthesis via A2A receptor |
| Hyaluronic Acid 20–100 kDa |
1–2% | Microchannel delivery + dermal hydration |
| Hyaluronic Acid >1 MDa |
0.5–1% | Surface calming + film formation |
| Centella Asiatica | 0.5–2% | Asiaticoside anti-inflammatory, soothing |
| Panthenol (B5) | 1–2% | Wound healing, barrier repair |
| Allantoin | 0.2–0.5% | Soothing, stimulates cell proliferation |
Clinic supply
CUVA supplies direct to aesthetic clinics, dermatology practices, and medspas across Europe. No distributor margin. Full documentation included with every order.
Sample packs available. Try R1 in-clinic before committing to a stock order. Every sample pack includes a full CoA, ingredient dossier, and patient aftercare card.
Clinical evidence
The data points on this site reference published, peer-reviewed studies on GHK-Cu and PDRN mechanisms and microneedling delivery. CUVA R1 is a cosmetic product. No therapeutic or medical outcomes are implied.
All references cite published peer-reviewed studies on ingredient mechanisms and delivery conditions. Results reflect specific experimental or clinical conditions in those studies and are not a guarantee of product outcomes. CUVA R1 is a cosmetic product regulated under EU Regulation EC 1223/2009. No therapeutic or medical claims are made or implied.
Trade enquiry
Request a trade sample pack or wholesale pricing. We respond within one business day.
Trade enquiries only. We respond within one business day.
Received. We'll be in touch within one business day.